Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-paclitaxel + carboplatin versus solvent-based paclitaxel + carboplatin in advanced squamous cell lung cancer
ChiCTR1900021857Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel and carboplatin in Pulmonary squamous cell carcinoma (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Objective response rate. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900021857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021857.